Sun Pharma Advanced Research Company Company Description

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally.

It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures.

In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson’s disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer’s disease.

Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial.

Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials.

The company was incorporated in 2006 and is based in Mumbai, India.

Sun Pharma Advanced Research Company Limited

Country	India
Founded	2006
Industry	Pharmaceutical Preparations
Employees	409
CEO	Anilkumar Raghavan

Contact Details

Address: 17/B, Mahal Industrial Estate Mumbai, 400093 India
Phone	91 22 6645 5645
Website	sparc.life

Stock Details

Ticker Symbol	532872
Exchange	Bombay Stock Exchange
Fiscal Year	April - March
Reporting Currency	INR
SIC Code	2834

Key Executives

Name	Position
Anilkumar Raghavan	Chief Executive Officer
Anup Rathi	Chief Financial Officer
Nitin Dharmadhikari	Chief Operating Officer
Jaydeep Issrani	Head of Investor Relations